51100-47-1

Basic information

• Product Name: Heptanoic acid, 7-bromo-, 1,1-dimethylethyl ester
• Synonyms: t-butyl 7-bromoheptanoate;Heptanoic acid,7-bromo-,1,1-dimethylethyl ester;7-bromoheptanoic acid t-butyl ester;t-butyl 7-bromoheptonate;tert-butyl-1-bromoheptanoate
• CAS NO: 51100-47-1
• Molecular Formula: C11H21BrO2
• Molecular Weight: 265.191
• Mol File: 51100-47-1.mol

Chemical Properties

• Boiling Point: 274.7±23.0 °C(Predicted)
• Density: 1.169±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Heptanoic acid, 7-bromo-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Heptanoic acid, 7-bromo-, 1,1-dimethylethyl ester(51100-47-1)
• EPA Substance Registry System: Heptanoic acid, 7-bromo-, 1,1-dimethylethyl ester(51100-47-1)

Safety Data

• Hazardous Substances Data: 51100-47-1(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis Industry:
Heptanoic acid, 7-bromo-, 1,1-dimethylethyl ester is used as a raw material for the synthesis of other chemicals. Its unique structure allows it to be a valuable intermediate in the production of various compounds, contributing to the development of new chemical products.
Used as a Flavoring Agent in Food Industry:
Heptanoic acid, 7-bromo-, 1,1-dimethylethyl ester is utilized as a flavoring agent in some food products. Its distinct properties enable it to enhance the taste and aroma of certain foods, providing a unique flavor profile to the final product.
Safety Precautions:
It is crucial to handle Heptanoic acid, 7-bromo-, 1,1-dimethylethyl ester with care, as it can be hazardous if not used properly. Proper safety measures should be taken to minimize any risks associated with its use, ensuring the well-being of individuals and the environment.

Upstream product

• 111-24-0 1,5-dibromo-pentane 
• 1207973-75-8 lithium tert-butyl acetate 
• 540-88-5 acetic acid tert-butyl ester 
• 680-31-9 N,N,N,N,N,N-hexamethylphosphoric triamide 
• 30515-28-7 7-bromoheptanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 75-65-0 tert-butyl alcohol 
• 98946-18-0 tert-Butyl 2,2,2-trichloroacetimidate 

Downstream Products

• 54005-76-4 tert-butyl 7-iodoheptanoate 
• 152754-52-4 (1R)-3-phenyl-1-(3-((7-tert-butoxy-7-oxoheptanyl)oxy)phenyl)propan-1-ol 
• 79496-53-0 3-(6-carboxyhexyl)-4-(3-cyclohexyl-3-hydroxypropyl)-1,3,4-thiadiazolidine-2,5-dione 
• 79496-55-2 3-(6-t-butyloxycarbonylhexyl)-4-(3-cyclohexyl-3-hydroxypropyl)-1,3,4-thiadiazolidine-2,5-dione 

Relevant articles and documents

RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS

Provided herein are RAS protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RAS-mediated disorder, disease, or condition.

MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES

The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

A Bioorthogonal Click Chemistry Toolbox for Targeted Synthesis of Branched and Well-Defined Protein–Protein Conjugates

Bioorthogonal chemistry holds great potential to generate difficult-to-access protein–protein conjugate architectures. Current applications are hampered by challenging protein expression systems, slow conjugation chemistry, use of undesirable catalysts, or often do not result in quantitative product formation. Here we present a highly efficient technology for protein functionalization with commonly used bioorthogonal motifs for Diels–Alder cycloaddition with inverse electron demand (DAinv). With the aim of precisely generating branched protein chimeras, we systematically assessed the reactivity, stability and side product formation of various bioorthogonal chemistries directly at the protein level. We demonstrate the efficiency and versatility of our conjugation platform using different functional proteins and the therapeutic antibody trastuzumab. This technology enables fast and routine access to tailored and hitherto inaccessible protein chimeras useful for a variety of scientific disciplines. We expect our work to substantially enhance antibody applications such as immunodetection and protein toxin-based targeted cancer therapies.

Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)

The estrogen receptor (ER) is a validated target for the treatment of estrogen receptor-positive (ER+) breast cancer. Here, we describe the design, synthesis, and extensive structure-activity relationship (SAR) studies of small-molecule ERα degraders base

Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells

Synergistic-to-additive antileukemic interactions of piperlongumine (PL) and HDAC inhibitor (HDACi) SAHA (Vorinostat) provide a compelling rationale to construct PL-HDACi hybrids, such as 1-58, which recapitulated the synergism between the parental compounds in high-risk and chemoresistant AML cells. Both PL and HDACi components, either in combination or in hybrid molecules, are essential for inducing significant DNA damage and apoptosis. Introducing C2-chloro substituent to 1-58 yielded 3-35 with increased cytotoxicity but decreased selectivity in noncancerous MCF-10A cells; eliminating C7-C8 olefin of PL obtained 3-31/3-98 scaffolds which were still more active than PL or SAHA in AML and were well-tolerated by MCF-10A cells. The HDACi function was crucial for modulating expression of DNA repair and apoptosis-related proteins. Collectively, PL and SAHA hybrids are potent, multifunctional anti-AML agents, acting in part, by interfering cellular GSH defense, suppressing expression of DNA repair and pro-survival proteins, and inducing expression of pro-apoptotic proteins.

Carboxy-imidazole derivatives, compositions and use

The imidazole derivatives of the general formula: STR1 [wherein m represents an integer of 4 to 9, R1 represents a hydrogen atom or a straight- or branched-chain alkyl group containing from 1 to 12 carbon atoms, and one of R2 and R3 represents a hydrogen atom, and the other represents a halogen atom or a phenyl group, or R2 and R3 together represent --(CH2)n --(in which n represents an integer of 4 to 6) or represent =CH2 ] and non-toxic salts thereof, which have a specifically inhibitory effect on the biosynthesis of thromboxane A2 (abbreviated as TXA2 hereafter) and are, therefore, useful as treating agents for diseases caused by TXA2 such as inflammation, cerebral apoplexy, myocardial infarction, acute cardiac death, cardiostenosis and thrombus etc.